UK markets open in 1 hour 29 minutes
NIKKEI 225
38,236.07 -37.98 (-0.10%) HANG SENG
18,423.14 +216.01 (+1.19%) CRUDE OIL
79.19 +0.24 (+0.30%) GOLD FUTURES
2,315.50 +5.90 (+0.26%) DOW
38,225.66 +322.37 (+0.85%) Bitcoin GBP
47,484.88 +1,860.27 (+4.08%)
Atara Biotherapeutics, Inc. (0HIY.L)
LSE - LSE Delayed price. Currency in USD
Add to watchlist
At close: 07:12PM BST
| Previous close | 0.7500 |
| Open | 0.0000 |
| Bid | 0.0000 x N/A |
| Ask | 0.0000 x N/A |
| Day's range | 0.0000 - 0.0000 |
| 52-week range | |
| Volume | |
| Avg. volume | 52,102 |
| Market cap | 163,167 |
| Beta (5Y monthly) | 0.72 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
Atara Biotherapeutics (ATRA) Reports Q4 Loss, Tops Revenue Estimates
Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of 8.20% and 73.91%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
- Simply Wall St.
After losing 76% in the past year, Atara Biotherapeutics, Inc. (NASDAQ:ATRA) institutional owners must be relieved by the recent gain
Key Insights Institutions' substantial holdings in Atara Biotherapeutics implies that they have significant influence...
- GuruFocus.com
Seth Klarman's Exit from Atara Biotherapeutics Inc
Renowned value investor Seth Klarman (Trades, Portfolio), through The Baupost Group, has recently divested the firm's entire stake in Atara Biotherapeutics Inc (NASDAQ:ATRA). This move has had a noticeable impact on Klarman's portfolio, reducing its exposure to the healthcare sector.
© 2024 Yahoo. All rights reserved.